Greencare Capital

Greencare Capital plc is an investment vehicle focused on investment opportunities in, and acquisitions of, companies and businesses in the rapidly changing regulatory environment surrounding the legal CBD wellness sectors, hemp and other plant-based wellness products.

Admission to the AQUIS Stock Exchange (formerly NEX)
The Company announced on Tuesday 17 December that it is seeking Admission of its entire issued share capital, as enlarged by way of a recent share subscription, to the AQUIS Stock Exchange (formerly NEX). It is anticipated that Admission will become effective and dealings in the Company’s Ordinary Shares will commence on 30 December.

ABOUT US

The Green Care Capital is an Investment Vehicle to identify investment opportunities in and acquisitions of companies and businesses in the rapidly changing regulatory environment surrounding legal Medicinal Hemp as well as investment opportunities within the CBD wellness sectors and other plant-based medicines.

Greencare Capital identifies business acquisition opportunities in new cultivation technologies, products and services related to the evolution of hemp as an agricultural product, in Hemp and CBD wellness sectors or in other plant-based medicines.

Our vision is to provide investors the best business opportunities in the pharmaceutical field and medical use of the plants. Driven by passion we look forward in innovation and technologies to guarantee our clients diversified range of investment tools.

As we strive to improve people’s lives and generate long-term value for our stakeholders, we are guided by these principles:

People and Community CareWe believe in fostering the most valuable global cannabis community comprised of passionate and daring people.
Quality ProductsWe believe in developing innovative and meaningful products that meet the needs and exceed the expectations of out consumers
Integrity & LeadershipWe take pride in leading the industry forward responsibly

MARKET OPPORTUNITIES

The global laws and regulations relating to Hemp and plant based medicines are continually evolving.

The Board will monitor these changes, particularly where they apply to Europe, to ensure that the Company can take advantage of new investment opportunities as they become available.

There are over 100 active compounds contained in Cannabis plants, with cannabinoids and terpenes being the two largest groups. Two cannabinoids are the most significant of these compounds:

tetrahydrocannabinol (THC), the main psychoactive substance in cannabis which is responsible its euphoric effects;
cannabidiol (CBD) which produces the calming effects.

It is the terpenes in Cannabis which are responsible for its strong smell.

In the United Kingdom THC and other cannabinoids are deemed controlled substances under the MDA 1971, while CBD is not deemed to be a controlled substance.

The Cannabis market has four distinct categories:

Medical Cannabis – products derived or based on Cannabis plants and taken by patients as directed by a medical practitioner for the treatment of specific diseases or conditions such as epilepsy and multiple sclerosis;
Pharmaceutical Cannabis – medical products formulated using pure cannabinoids either derived from plants or synthetically created, which have obtained full clinical approval as pharmaceuticals;
Recreational cannabis – Cannabis used for non-medical purposes and obtained via illicit sources due to its illegality in many countries including the UK.
CBD wellness – a wide range of consumer products based on Hemp-derived CBD oils which do not contain any controlled substances and are consequently regulated as food supplements;

In addition to the Cannabis market, there is also a substantial Hemp industry which has four main product groups; fibres, shivs, pharmaceuticals and seeds.